Analysis shows that the U.S. biotech sector is yet to achieve significant growth momentum compared to China’s surging industry performance in 2025. Public market previews and reports from BioCentury indicate that China’s biotech ecosystem is advancing briskly, while U.S. firms remain in a period of consolidation and await catalysts to spur liftoff. This divergence highlights evolving global dynamics in biotech innovation and investment.